Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Director/PDMR Shareholding
By: Nasdaq / GlobeNewswire - 14 Dec 2018Back to overview list

Director/PDMR Shareholding

December 14, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”)

Notification of transactions by person discharging managerial responsibilities

1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameBill Mordan
2.Reason for the notification
a)Position / statusGeneral Counsel and Company Secretary - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016. In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP:

a. 100% of the PSUs vested pursuant to applicable performance conditions;

b. vesting of the PSUs was accelerated relative to the normal vesting date; and

(ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the PSUs from the award date to the date of vesting. (Details of related disposal of ADSs are referenced in section 5. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$08,853
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of PSUs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the PSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.66253,983
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameJoanne Cordeiro
2.Reason for the notification
a)Position / statusChief Human Resources Officer – PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on May 1, 2018.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP:

a. 100% of the PSUs vested pursuant to applicable performance conditions;

b. vesting of the PSUs was accelerated relative to the normal vesting date; and

(ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the PSUs from the award date to the date of vesting.

(Details of related disposal of ADSs are referenced in section 5. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$012,050
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of PSUs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the PSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.66255,420
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ
6.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP:

a. 100% of the PSUs vested pursuant to applicable performance conditions;

b. vesting of the PSUs was accelerated relative to the normal vesting date; and (ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the PSUs from the award date to the date of vesting.
(Details of related disposal of ADSs are referenced in section 7. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$0494
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
7.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of PSUs referenced in section 6. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the PSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.6625224
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ
8.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on August 24, 2017.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP, vesting of the RSUs was accelerated relative to the normal vesting date; and (ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting.
(Details of related disposal of ADSs are referenced in section 9. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$01,410
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
9.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of RSUs referenced in section 8. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.6625633
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ
10.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 28, 2017.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP, vesting of the RSUs was accelerated relative to the normal vesting date; and (ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting.
(Details of related disposal of ADSs are referenced in section 11. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$0104
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
11.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of RSUs referenced in section 10. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.662547
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ
12.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP, vesting of the RSUs was accelerated relative to the normal vesting date; and (ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting.
 (Details of related disposal of ADSs are referenced in section 13. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$0173
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
13.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of RSUs referenced in section 12. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.662579
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NamePerry Sternberg
2.Reason for the notification
Related companies:ShangPharma Corp (SHP) | Shire Pharmaceuticals Ireland Ltd
Copyright 2018 Nasdaq / GlobeNewswire Back to overview list
to the top ↑